Disfunción tiroidea autoinmunitaria de presentación variable en una paciente tratada con interferón-α

Interferon-α is the main therapeutic agent in patients with chronic active hepatitis C. Autoimmune thyroid disorders are a frequent and well-known adverse effect of interferon-α. We report the case of a patient with posttransfusion chronic hepatitis C treated with interferon-α on 2 occasions with an interval of 7 years. After the first cycle of interferon-α therapy she presented thyrotoxicosis due to Graves’ disease with 2 relapses. After the second treatment, the patient showed hypothyroidism with positive thyroid antibodies.